In the fiercely competitive space of Duchenne muscular dystrophy (DMD) gene therapy, Regenxbio’s latest data on RGX-202 has drawn significant attention. However, contrary to high expectations, it appears to match, rather than outperform, Sarepta’s Elevidys, which received approval in June 2023. This comes despite promising interim Phase I/II results from the AFFINITY DUCHENNE trial. The […]
Category: Regenxbio news
Expert Analysis of Regenxbio by 8 Analysts
In the dynamic landscape of biotech innovation, Regenxbio Inc. stands tall as a beacon of hope for those burdened by genetic defects. This biotech company is trailblazing a path in the development and commercialization of recombinant adeno-associated virus gene therapy, positioning it at the forefront of revolutionary therapeutic techniques. Regenxbio’s game-changing platform is designed to […]